<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284735</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0930</org_study_id>
    <secondary_id>2019-A03087-50</secondary_id>
    <nct_id>NCT04284735</nct_id>
  </id_info>
  <brief_title>Lysophosphatidic Acid / Autotaxin Axis in Rheumatoid Lung Disease</brief_title>
  <acronym>LYSLUNG</acronym>
  <official_title>Role of Lysophosphatidic Acid and Autotaxin in Rheumatoid Arthritis-associated Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a common chronic systemic autoimmune relapsing disease&#xD;
      characterized by joint inflammation. Beside arthritis leading to progressive joint damage and&#xD;
      loss of function, RA is also associated to extraarticular inflammatory conditions such as&#xD;
      interstitial lung disease (ILD). This one develops in 30% of all RA patients with a median&#xD;
      survival expectancy of 3 to 10 years once symptomatic. Unfortunately, there is no medical&#xD;
      care recommendation so far as the pathophysiology is unknown. However, ILD share many&#xD;
      similarities with idiopathic pulmonary fibrosis (IPF).&#xD;
&#xD;
      Autotaxin (ATX), due to its lysophospholipase activity, produces a bioactive lipid,&#xD;
      lysophosphatidic acid (LPA) under inflammation. LPA has pleiotropic actions inducing cell&#xD;
      proliferation, survival, motility and differentiation. Increased ATX and LPA levels have been&#xD;
      detected in synovial fluid of RA patients and in IPF patients. ATX is also currently the&#xD;
      target for a phase 3 clinical trial in IPF.&#xD;
&#xD;
      Given the previous described role of ATX/LPA axis in arthritis and inflammation-induced bone&#xD;
      loss in RA and the similarities between RA-ILD and IPF, the investigators hypothesized that&#xD;
      ATX/LPA axis may be also an attractive drug target for this pulmonary condition in RA and&#xD;
      therefore that ATX and LPA may be increased in sputum from RA patients with ILD in comparison&#xD;
      with sputum from RA patients without ILD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ATX and LPA levels in sputum from RA patients with ILD in comparison with sputum from RA patients without ILD</measure>
    <time_frame>Month 30</time_frame>
    <description>All the samples will be frozen and ATX and LPA levels will be assessed in the plasma and sputum at the same time, at the end of the recruitment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between ATX and LPA levels and severity of RA-ILD estimated by tomodensitometry</measure>
    <time_frame>Month 24</time_frame>
    <description>Determine the correlation between ATX and LPA levels and the severity of CT scan pulmonary involvement*.&#xD;
*Diffuse interstitial lung disease is defined as an attack compatible with the thoracic scanner in thin sections according to international criteria with or without associated clinical signs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with RA and without ILD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with RA and ILD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quantitative ATX and LPA determination in plasma and sputum</intervention_name>
    <description>Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (&quot;cases&quot;) and in plasma and sputum from RA patients without ILD (&quot;controls&quot;) after sputum induction using hypertonic saline inhalation</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion criteria&#xD;
&#xD;
          -  Subject aged ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  Patient with RA with ACPA in the state phase, meeting ACR / EULAR 2010 criteria&#xD;
&#xD;
          -  For female subjects:&#xD;
&#xD;
               -  Likely to procreate: negative pregnancy test at the inclusion visit and use of an&#xD;
                  effective method of contraception (hormonal contraceptives, intrauterine devices,&#xD;
                  vasectomized partner, abstinence) started at least 1 month before inclusion and&#xD;
                  continued during the entire study.&#xD;
&#xD;
               -  Inability to procreate: menopause (absence of a rule for at least 1 year) or&#xD;
                  hysterectomy or bilateral oophorectomy or tubal ligation.&#xD;
&#xD;
          -  Subject having given written consent to participate in the study&#xD;
&#xD;
          -  Subject affiliated to the Social Security scheme or benefiting from an equivalent&#xD;
             scheme&#xD;
&#xD;
        Additional inclusion criteria for cases (RA patients with PID):&#xD;
&#xD;
        - PID is defined as damage compatible with the thoracic scanner in thin sections according&#xD;
        to international criteria with or without associated clinical signs.&#xD;
&#xD;
        Additional inclusion criteria for control patients (RA patients without symptomatology&#xD;
        without PID)&#xD;
&#xD;
        - No functional lung complaints&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General exclusion criteria&#xD;
&#xD;
          -  Vulnerable patient within the meaning of current French legislation (deprived of&#xD;
             liberty by judicial or administrative decision, under guardianship or curatorship or&#xD;
             under the protection of justice)&#xD;
&#xD;
          -  Patient not fluent in French&#xD;
&#xD;
          -  Woman breastfeeding or planning a pregnancy for the duration of the study&#xD;
&#xD;
          -  Patient in exclusion period after participating in another clinical trial or in the&#xD;
             process of participating in another clinical trial involving an experimental product&#xD;
&#xD;
          -  Patient with occupational exposure to particles known to be responsible for PID&#xD;
             (silica, etc.)&#xD;
&#xD;
          -  Patient with an autoimmune disease other than RA or an auto-inflammatory disease&#xD;
&#xD;
        Non-inclusion criteria for cases (RA patients with PID):&#xD;
&#xD;
        - Patient with a history of asthma, COPD or any other pulmonary pathology or pulmonary&#xD;
        symptom unrelated to PID&#xD;
&#xD;
        Non-inclusion criteria for control patients (RA patients without PID)&#xD;
&#xD;
        - Patient with a history of asthma, COPD, any other pulmonary pathology, any pulmonary&#xD;
        symptom or any pulmonary CT abnormality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne COURY-LUCAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabienne COURY-LUCAS, MD</last_name>
    <phone>04 78 86 56 95</phone>
    <phone_ext>+33</phone_ext>
    <email>fabienne.coury@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne COURY-LUCAS, MD</last_name>
      <phone>04 78 86 56 95</phone>
      <phone_ext>+33</phone_ext>
      <email>fabienne.coury@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Fabienne COURY-LUCAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Autotaxin</keyword>
  <keyword>Lysophosphatidic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

